Relugolix

• Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending
  2024-518388-37-00 Phase II 1 country Fondazione Radioterapia Oncologica Onlus
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 Phase II/III 2 countries Ziekenhuis Aan De Stroom
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting
  2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
• REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermed… Recruiting
  2025-521170-33-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting
  2024-520156-22-00 Phase II 7 countries Novartis Pharma AG
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
• Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTR… Recruiting
  2023-504704-28-00 Phase II 1 country Central Finland Hospital District Central Finland Hospital Nova
• Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting
  2022-502373-42-00 Phase III 1 country UZ Leuven
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended
  2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended
  2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended
  2022-502634-52-00 Phase III 2 countries Friedrich-Schiller-Universitaet Jena
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III 13 countries Janssen - Cilag International
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-503254-12-00 Phase III 10 countries Janssen - Cilag International

Showing 1–14 of 14 trials